Oral compositions for absorption of phosphorus compounds

Details Oral compositions for absorption of phosphorus compounds Oral compositions for absorption of phosphorus compounds

2005-11-29

2010-10-19

Olson, Eric S (Department: 1623)

Drug, bio-affecting and body treating compositions

Chewing gum type

C424S078100, C424S078110, C424S078120, C424S686000, C424S687000, C424S600000, C424S715000

Reexamination Certificate

active

07815898

ABSTRACT:
The present invention provides medicaments useful for reducing phosphorus serum level, especially in those subjects affected from hyperphosphatemia. More specifically, the present invention relates to pharmaceutical compositions to be administered by oral route in fasting periods, in order to absorb phosphorus compounds from fluids of the enteric tract, especially from saliva.

REFERENCES:
patent: 4163777 (1979-08-01), Mitra
patent: 4181718 (1980-01-01), Mason et al.
patent: 4814176 (1989-03-01), Makino et al.
patent: 5496545 (1996-03-01), Holmes-Farley et al.
patent: 5968976 (1999-10-01), Murrer et al.
patent: 2003/0138518 (2003-07-01), Kiefer et al.
patent: 0 426 098 (1991-05-01), None
patent: 0 793 960 (1997-09-01), None
patent: 1 046 410 (2000-10-01), None
patent: 62-132830 (1987-06-01), None
patent: 05-213762 (1993-08-01), None
patent: 02/051259 (2002-07-01), None
patent: 2005/018651 (2005-03-01), None
patent: 2005/041902 (2005-05-01), None
patent: WO2006/050314 (2006-05-01), None
The Merck Index, Twelfth Edition, published 1996 by Merck Research Laboratories, pp. 270-278 and 968-971.
Locateli et al., “The importance of early detection of chronic kidney disease” Nephrol. Dial. Transplant. (2002) vol. 17 suppl. 11, pp. 2-7.
Tonelli et al., N. Engl. J. Med. (2010) vol. 362, pp. 1312-1324.
Savica et al., J. Am. Soc. Nephrol. (2009) vol. 20 pp. 639-644.
“Fosrenol (R) Approved to Reduce Phosphorus Levels in End-Stage Renal Disease Patients”, Shire Pharmaceuticals Group PLC (2004); retrieved from http://www.newswise.com/articles/view/507957 (Online 2006).
Schiller et al., “Effect of the Time of Administration of Calcium Acetate on Phosphorus Binding”, New England Journal of Medicine, vol. 320, pp. 1110-1113 (1989).
Smith et al., “Aluminum Hydroxide: Evaluation of Two Dosage Forms and Two Dosing Schedules in Reducing Intestinal Phosphate Absorption”, American Journal of Hospital Pharmacy, vol. 35, pp. 58-61 (1978).
Salivary Phosphorous Binding: A Novel Approach to Control Hyperphosphatemia. (J. Am. Soc. Nephrol. 20:460-462, 2009).
Tonelli et al., N. Engl. J. Med. 2010;362:1312-24, 1313.
Savica et al., J. Am. Soc. Nephrol., 20:939-644, 2009.
McMillan, James L.; The Merck Manual; “Chronic Kidney Disease—Renal Failure”; Rev. Dec. 2007; 7 pages. http://www.merck.com/mmpe/sec17/ch233/ch233c.html.
“The Merck Index—An Encyclopedia Of Chemicals, Drugs and Biologicals”; Third Edition, Merck & Co., Inc.; 3 pages, (2001).
Salusky; “A New Era In Phosphate Binder Therapy: What Are The Options?”; Kidney International, 2006 (70) S10-S15; 6 pages.
FDA approved label for Renagel® (sevelamer) (Oct. 2007).
FDA approved label for Fosrenol® (lanthanum carbonate) (revised Oct. 2009).
Chewing Gum Helps Treat Hyperphosphatemia in Kidney Disease Patients (Feb. 2009).

Affiliated with

Also associated with

Rating

Oral compositions for absorption of phosphorus compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oral compositions for absorption of phosphorus compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral compositions for absorption of phosphorus compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4196911